Research ExplorerPublicationsCefiderocol in Critically Ill Patients with Multi-Drug Resis...

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

Standard

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. / König, Christina; Both, Anna; Rohde, Holger; Kluge, Stefan; Frey, Otto R.; Röhr, Anka C; Wichmann, Dominic.

In: ANTIBIOTICS-BASEL, Vol. 10, No. 6, 649, 28.05.2021, p. 649.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

König, C, Both, A, Rohde, H, Kluge, S, Frey, OR, Röhr, AC & Wichmann, D 2021, 'Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance', ANTIBIOTICS-BASEL, vol. 10, no. 6, 649, pp. 649. https://doi.org/10.3390/antibiotics10060649

APA

König, C., Both, A., Rohde, H., Kluge, S., Frey, O. R., Röhr, A. C., & Wichmann, D. (2021). Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. ANTIBIOTICS-BASEL, 10(6), 649. [649]. https://doi.org/10.3390/antibiotics10060649

Vancouver

König C, Both A, Rohde H, Kluge S, Frey OR, Röhr AC et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. ANTIBIOTICS-BASEL. 2021 May 28;10(6):649. 649. https://doi.org/10.3390/antibiotics10060649

Bibtex

@article{0adcb9b785d94c77b9b5c22173d37cff,
title = "Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance",
abstract = "Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer's dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended.",
author = "Christina K{\"o}nig and Anna Both and Holger Rohde and Stefan Kluge and Frey, {Otto R.} and R{\"o}hr, {Anka C} and Dominic Wichmann",
year = "2021",
month = may,
day = "28",
doi = "10.3390/antibiotics10060649",
language = "English",
volume = "10",
pages = "649",
journal = "ANTIBIOTICS-BASEL",
issn = "2079-6382",
publisher = "MDPI Multidisciplinary Digital Publishing Institute",
number = "6",

}

RIS

TY - JOUR

T1 - Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

AU - König, Christina

AU - Both, Anna

AU - Rohde, Holger

AU - Kluge, Stefan

AU - Frey, Otto R.

AU - Röhr, Anka C

AU - Wichmann, Dominic

PY - 2021/5/28

Y1 - 2021/5/28

N2 - Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer's dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended.

AB - Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer's dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended.

U2 - 10.3390/antibiotics10060649

DO - 10.3390/antibiotics10060649

M3 - SCORING: Journal article

VL - 10

SP - 649

JO - ANTIBIOTICS-BASEL

JF - ANTIBIOTICS-BASEL

SN - 2079-6382

IS - 6

M1 - 649

ER -